Adverse events following immunization with vaccines containing adjuvants.
about
Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral LeishmaniasisImmunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study.Possible Triggering Effect of Influenza Vaccination on Psoriasis.Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing.Murine hypothalamic destruction with vascular cell apoptosis subsequent to combined administration of human papilloma virus vaccine and pertussis toxin.Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants.Severe manifestations of autoimmune syndrome induced by adjuvants (Shoenfeld's syndrome).Autoimmune reaction after anti-tetanus vaccination-description of four cases and review of the literature.Prophylactic properties of a Leishmania-specific hypothetical protein in a murine model of visceral leishmaniasis.[Adverse ocular effects of vaccinations].Phage-fused epitopes from Leishmania infantum used as immunogenic vaccines confer partial protection against Leishmania amazonensis infection.The putative role of environmental aluminium in the development of chronic neuropathology in adults and children. How strong is the evidence and what could be the mechanisms involved?Unraveling the soul of autoimmune diseases: pathogenesis, diagnosis and treatment adding dowels to the puzzle.Chronic fatigue syndrome and fibromyalgia following immunization with the hepatitis B vaccine: another angle of the 'autoimmune (auto-inflammatory) syndrome induced by adjuvants' (ASIA).Influenza Vaccine and Autoimmune Diseases
P2860
Q27318412-729F1ED1-2354-4D40-A069-C59A61856CCCQ34621859-36CD3E5F-57DB-4188-AAEE-D7715F2AC854Q36034718-45523EE5-CD3C-454A-AFD7-BBE100B5603EQ37087055-44277C46-0B14-433A-BFB4-C00C6192ED28Q37408584-C49BDCDD-DB71-47AF-9B7B-397D3DB18505Q38125512-BB90B719-C3B7-499A-812C-255CD5745059Q38895709-06717B48-9E55-4AC8-816C-D29365D18860Q38902486-788A0415-4540-4516-A5F0-A30DA98AC39DQ39156593-703634B2-4941-4092-BB78-B966BEBAB837Q40631486-A38FD9B0-8D71-4E8D-B355-849960961254Q41146226-5C1C74A8-9020-40C9-8EA8-E6E146C0ABEEQ41689625-6F4015CF-CBF8-42D2-AEC5-435190F44576Q43734009-1EADDDC9-3FC3-41EF-A22A-46ACEF368862Q55058719-DF945880-8786-4F51-9786-1A546F462AB5Q58051969-2BF7CE3B-E9AB-4E16-AFBA-FDE3A4A2F2AC
P2860
Adverse events following immunization with vaccines containing adjuvants.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Adverse events following immunization with vaccines containing adjuvants.
@en
type
label
Adverse events following immunization with vaccines containing adjuvants.
@en
prefLabel
Adverse events following immunization with vaccines containing adjuvants.
@en
P2093
P2860
P1433
P1476
Adverse events following immunization with vaccines containing adjuvants.
@en
P2093
A G Bernard-Medina
E Landeros Navarro
G Martínez-Bonilla
P Paredes-Casillas
S Cerpa-Cruz
S Gutiérrez-Ureña
P2860
P2888
P304
P356
10.1007/S12026-013-8400-4
P577
2013-07-01T00:00:00Z
P6179
1036774247